Sarepta director exercises 10,500-share stock option

Sarepta Therapeutics director M. Kathleen Behrens reported an option exercise and related share withholding.

Rhea-AI Filing Summary

Sarepta Therapeutics director M. Kathleen Behrens reported an option exercise and related share withholding. On January 27, 2026, she exercised a stock option for 10,500 shares of common stock at $13.71 per share, converting a derivative award into owned stock.

To cover the option exercise cost, 6,494 shares of common stock were withheld by Sarepta at a price of $22.17 per share, as explained in the footnote. After these transactions, she held 197,482 shares of common stock directly and 10,000 shares indirectly through a trust.

Insider Trade Summary

10,500 shares exercised/converted

Exercise 4 txns

Insider BEHRENS M KATHLEEN

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	10,500	$0.00	$0.00
Exercise	Common Stock	10,500	$13.71	$144K
Exercise Price or Tax Liability	Common Stock	6,494	$22.17	$144K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 197,482 shares (Direct); Common Stock — 10,000 shares (Indirect, By Trust)

Footnotes (1)

1. F1. Represents shares withheld by the Issuer to satisfy payment by the Reporting Person of the option exercise price. The Reporting Person holds the exercised shares not withheld by the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Sarepta (SRPT) director M. Kathleen Behrens report?

Director M. Kathleen Behrens reported exercising a stock option for 10,500 shares of Sarepta common stock on January 27, 2026, converting a derivative award into directly owned shares as disclosed in the Form 4 filing.

How many Sarepta (SRPT) shares were withheld to cover the option exercise?

Sarepta withheld 6,494 shares of common stock at a price of $22.17 per share. According to the footnote, these shares were retained by the company to satisfy payment of the option exercise price for the reported transaction.

What option exercise price was reported in the Sarepta (SRPT) Form 4?

The stock option exercised by M. Kathleen Behrens had an exercise price of $13.71 per share. She exercised options covering 10,500 shares of Sarepta common stock on January 27, 2026, as shown in the derivative securities table.

How many Sarepta (SRPT) shares does the director hold after this Form 4 transaction?

After the reported transactions, M. Kathleen Behrens directly owned 197,482 shares of Sarepta common stock and indirectly held 10,000 shares through a trust, according to the beneficial ownership columns in the Form 4.

What happened to the stock option reported in the Sarepta (SRPT) Form 4?

The reported stock option for 10,500 shares with a $13.71 exercise price was exercised on January 27, 2026. Following the exercise, the remaining number of derivative securities owned for that option position was reported as zero.

What indirect Sarepta (SRPT) holdings were disclosed for the director?

The Form 4 shows an indirect holding of 10,000 Sarepta shares classified as owned "By Trust." This reflects shares beneficially owned through a trust, separate from the director’s directly held 197,482 common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/29/2026 - 08:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BEHRENS M KATHLEEN

(Last) (First) (Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/27/2026		M		10,500	A	$13.71	203,976	D
Common Stock	01/27/2026		F(1)		6,494	D	$22.17	197,482	D
Common Stock								10,000	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.71	01/27/2026		M		10,500		02/28/2017	02/28/2026	Common Stock	10,500	$0	0	D

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy payment by the Reporting Person of the option exercise price. The Reporting Person holds the exercised shares not withheld by the Issuer.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for M. Kathleen Behrens	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.